Anzeige
Mehr »
Dienstag, 21.07.2026 - Börsentäglich über 12.000 News
42 Proben im Labor - Jetzt beginnt die spannendste Phase für diese Wolfram-Aktie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E19Y | ISIN: BE0974461940 | Ticker-Symbol: O6C1
Frankfurt
20.07.26 | 20:57
0,062 Euro
-8,89 % -0,006
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MDXHEALTH SA Chart 1 Jahr
5-Tage-Chart
MDXHEALTH SA 5-Tage-Chart

Aktuelle News zur MDXHEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.07.Mdxhealth receives Nasdaq non-compliance notice after $1 bid price breach1
02.07.Mdxhealth erhält Rüge der NASDAQ wegen Nichterfüllung der Mindestkursanforderung3
02.07.Mdxhealth receives Nasdaq minimum bid price deficiency notice3
02.07.MDxHealth SA - 6-K, Report of foreign issuer1
MDXHEALTH Aktie jetzt für 0€ handeln
02.07.MDxHealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency130IRVINE, California - July 2, 2026 (GlobeNewswire) - Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company...
► Artikel lesen
14.05.TD Cowen cuts MDxHealth stock price target on Medicare dispute6
14.05.Medicare-Streit: TD Cowen kappt Kursziel für MDxHealth drastisch-
13.05.MDxHealth Reports Q1 2026 Results: Full Earnings Call Transcript4
13.05.MDxHealth SA - 6-K, Report of foreign issuer2
13.05.MDxHealth SA GAAP EPS of -$0.17 misses by $0.02, revenue of $27.38M misses by $3.42M2
03.04.MDxHealth SA - S-8, Securities to be offered to employees in employee benefit plans6
16.03.MDxHealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026285Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California -...
► Artikel lesen
04.03.BTIG reiterates MDxHealth stock rating on strong volume growth3
04.03.BTIG bekräftigt MDxHealth-Rating nach starkem Volumenwachstum2
26.02.MDxHealth SA - 6-K, Report of foreign issuer1
12.02.Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 261
11.02.MDxHealth SA - 6-K, Report of foreign issuer1
12.01.MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences316MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences IRVINE, CA - January 12, 2026 (GlobeNewswire) -...
► Artikel lesen
12.11.25MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025601Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 Q3 revenues increased by 18% to $27.4 millionAdjusted EBITDA profitability of $1.0 million for Q3Acquisition...
► Artikel lesen
15.09.25MDxHealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne690Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne IRVINE, CA, and HERSTAL, BELGIUM - September 15, 2025 (GlobeNewswire) - MDxHealth SA (NASDAQ: MDXH) (the "Company" or...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1